TrialClinical genitourinary cancer2019

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC).

Ruchitbhai Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.